508 related articles for article (PubMed ID: 18473844)
21. Advanced glycation end products and the progressive course of renal disease.
Heidland A; Sebekova K; Schinzel R
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S100-6. PubMed ID: 11576932
[TBL] [Abstract][Full Text] [Related]
22. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
[TBL] [Abstract][Full Text] [Related]
23. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
24. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
[TBL] [Abstract][Full Text] [Related]
25. The renin-angiotensin system and diabetic nephropathy.
Gurley SB; Coffman TM
Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
[TBL] [Abstract][Full Text] [Related]
26. Phosphatidylinositol 3'-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products.
Xu D; Kyriakis JM
J Biol Chem; 2003 Oct; 278(41):39349-55. PubMed ID: 12871951
[TBL] [Abstract][Full Text] [Related]
27. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
28. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
Thomas MC; Baynes JW; Thorpe SR; Cooper ME
Curr Drug Targets; 2005 Jun; 6(4):453-74. PubMed ID: 16026265
[TBL] [Abstract][Full Text] [Related]
29. Advanced glycation endproducts and diabetic nephropathy.
Makita Z; Yanagisawa K; Kuwajima S; Yoshioka N; Atsumi T; Hasunuma Y; Koike T
J Diabetes Complications; 1995; 9(4):265-8. PubMed ID: 8573743
[TBL] [Abstract][Full Text] [Related]
30. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
Kumar Pasupulati A; Chitra PS; Reddy GB
Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
[TBL] [Abstract][Full Text] [Related]
31. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
[TBL] [Abstract][Full Text] [Related]
32. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
33. Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-β1 expression in mesangial cells under diabetic conditions.
Kim YS; Jung DH; Lee IS; Pyun BJ; Kim JS
Phytomedicine; 2016 Apr; 23(4):388-97. PubMed ID: 27002409
[TBL] [Abstract][Full Text] [Related]
34. The podocyte in diabetic kidney disease.
Stitt-Cavanagh E; MacLeod L; Kennedy C
ScientificWorldJournal; 2009 Oct; 9():1127-39. PubMed ID: 19838599
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress and advanced glycation in diabetic nephropathy.
Coughlan MT; Mibus AL; Forbes JM
Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Pharmacol Res; 2012 Mar; 65(3):297-302. PubMed ID: 22100460
[TBL] [Abstract][Full Text] [Related]
37. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
38. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy.
Matsui T; Higashimoto Y; Nishino Y; Nakamura N; Fukami K; Yamagishi SI
Diabetes; 2017 Jun; 66(6):1683-1695. PubMed ID: 28385802
[TBL] [Abstract][Full Text] [Related]
39. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
Goh SY; Cooper ME
J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
[TBL] [Abstract][Full Text] [Related]
40. Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease.
Miranda-Díaz AG; Pazarín-Villaseñor L; Yanowsky-Escatell FG; Andrade-Sierra J
J Diabetes Res; 2016; 2016():7047238. PubMed ID: 27525285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
